CDC42

Cell division control protein 42 homolog · P60953 · CDC42 on Sugi Atlas →

9,110 patent compounds predicted against CDC42, 6,310 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Sanguinarium (SCHEMBL43290)	1.00	5/20
Sanguinarium (SCHEMBL123241)	0.97	5/20
Sanguinarium (SCHEMBL454298)	0.86	5/20
SCHEMBL543021	0.55	5/20
Sanguinarium (SCHEMBL1463519)	0.84	4/20
Hydrochloric Acid (SCHEMBL424548)	0.62	4/20
SCHEMBL424549	0.61	4/20
Hydrochloric Acid (SCHEMBL436618)	0.60	4/20
Ketorolac (SCHEMBL258489)	0.52	4/20
SCHEMBL2114515	0.41	4/20
SCHEMBL1521201	0.39	4/20
Ketorolac (SCHEMBL4103)	1.00	3/20
Ketorolac (SCHEMBL14891)	1.00	3/20
Ketorolac (SCHEMBL14892)	1.00	3/20
Ketorolac (SCHEMBL2221913)	0.92	3/20
Ketorolac (SCHEMBL5036)	0.79	3/20
Ketorolac (SCHEMBL977126)	0.79	3/20
Anirolac (SCHEMBL38909)	0.71	3/20
Chelerythrine (SCHEMBL195109)	0.67	3/20
Chelerythrine (SCHEMBL288915)	0.67	3/20

Clinical trials — most relevant to CDC42 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer	PHASE2	COMPLETED
Antioxidant Therapy With N-acetylcysteine for Learning and Motor Behavior in Children With Neurofibromatosis Type 1	PHASE2	COMPLETED
Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1	PHASE2	COMPLETED
Simvastatin + Cetuximab/Irinotecan in K-ras Mutant Colorectal Cancer (CRC)	PHASE2	COMPLETED
NEO100 and High-Grade Meningioma	PHASE2	RECRUITING
Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer	PHASE2	COMPLETED
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety	PHASE2	COMPLETED
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma	PHASE1/PHASE2	RECRUITING
Interleukin-2 Treatment for Wiskott-Aldrich Syndrome	PHASE1	COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors	PHASE1	NOT_YET_RECRUITING
ADRB3, ROCK2 and GEF Levels in Overactive Bladder Patients	nan	COMPLETED
Prospective Validation of a DNA Damage Repair-Hippo Pathway Signature in Patients With Advanced Gastric Cancer	nan	UNKNOWN
Study of the Pathophysiological Mechanisms Involved in Bleeding Events	nan	COMPLETED
The Relation of Microtubule-Associated Protein 2 and Cell Migration	nan	UNKNOWN
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
Role of Chemokine and Chemokine Receptor in Psoriasis	nan	WITHDRAWN
Identification of an Asthma Susceptibility Gene on 3P	nan	COMPLETED
Genetic Characterization of Parkinson's Disease	nan	COMPLETED
HCCBloodTest for Detection of Hepatocellular Carcinoma (HCC)	nan	COMPLETED
Studying the Role of Circulating Tumor Cell Clusters in Patients With High-risk Early Breast Cancer, Study GALIA	nan	RECRUITING
Genetic Identification (ID) of Segmental Dysplastic Nevi	nan	WITHDRAWN
Genetics and Psychopathology in the 22q11 Deletion Syndrome	nan	UNKNOWN
Molecular Mechanisms Underlying Prostate Cancer Disparities	nan	COMPLETED
Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial	nan	RECRUITING
Cell Membrane Potential Regulates Spatial-Specific Mechanoptosis Resistance and Metastasis in Colorectal Cancer Via Mechanotransduction and the PVR/CD96 Axis	nan	COMPLETED
Telomeres Length in Israeli Fibrotic ILD Patients	nan	ENROLLING_BY_INVITATION
IVM for Patients With Low Ovarian Response. Does it Improve IVFoutcomes and Does it Improve the Following IVF Cycle?	nan	UNKNOWN
Characterization of Microbiological and Genetic Features in Prostate Cancer and Their Association with Disease Stage	nan	ENROLLING_BY_INVITATION
Analysis of Brain Metastasis in Patients With Lung Cancer	nan	COMPLETED
Predictive Value of E-cadherin, β-catenin and SOX4 in Recurrence and/or Progression of Non-muscle Invasive Urinary Bladder Transitional Cell Carcinoma. A Retrospective Study	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CDC42 binder may also engage these)

Protein	Name	Similarity
P60766	—	1.000	P60766 →
P60952	—	1.000	P60952 →
Q8CFN2	—	1.000	Q8CFN2 →
Q007T2	—	1.000	Q007T2 →
Q2KJ93	—	1.000	Q2KJ93 →
Q4R4R6	—	1.000	Q4R4R6 →
Q90694	—	1.000	Q90694 →
Q16YG0	—	1.000	Q16YG0 →
Q17031	—	1.000	Q17031 →
Q05062	—	0.999	Q05062 →
Q29HY3	—	0.998	Q29HY3 →
C4YDI6	—	0.997	C4YDI6 →
P40793	—	0.996	P40793 →
Q01112	—	0.994	Q01112 →
O88931	—	0.992	O88931 →
P19073	—	0.989	P19073 →
Q03206	—	0.989	Q03206 →
Q9HF56	—	0.989	Q9HF56 →
P0CY33	—	0.988	P0CY33 →
Q9TU25	—	0.987	Q9TU25 →
P62747	—	0.987	P62747 →
P34148	—	0.986	P34148 →
P34146	—	0.986	P34146 →
Q05144	—	0.985	Q05144 →
Q09914	—	0.985	Q09914 →
RAC2	Ras-related C3 botulinum toxin substrate 2	0.985	landscape →
Q24814	—	0.984	Q24814 →
Q3ZBW5	—	0.984	Q3ZBW5 →
Q22038	—	0.984	Q22038 →
P40792	—	0.984	P40792 →